Apolizumab

Drug Profile

Apolizumab

Alternative Names: Hu1D10; Monoclonal antibody SMART 1D10; Remitogen; SMART 1D10 antibody

Latest Information Update: 31 Oct 2005

Price : $50

At a glance

  • Originator PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 11 Sep 2003 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
  • 26 Jun 2002 Discontinued - Phase-II for Non-Hodgkin's lymphoma in USA (Infusion)
  • 21 May 2002 Phase-I clinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top